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Abstract
Introduction: Familial Mediterranean fever (FMF) is an auto-inflammatory disease characterized by recurrent attacks
of fever and serositis. Limited data suggest that the prevalence of sacroiliitis is increased in patients with FMF. In
our present study, we assessed the prevalence of spondyloarthritis (SpA), including ankylosing spondylitis (AS),
among a cohort of FMF patients and their unaffected first-degree relatives (FDRs).
Methods: The current study cohort comprised a consecutive group of 201 unrelated patients with FMF and 319
FDRs (≥ 16 years old). These subjects were examined according to a standard protocol.
Results: A total of 157 FMF patients (78.1%) and 233 (73%) unaffected FDRs reported back pain. Fifteen FMF
patients (7.5%) and nine unaffected FDRs fulfilled the modified New York (mNY) criteria for AS. One additional FDR
with AS was identified after review of the medical records. None of the FMF patients with AS was HLA-B27
positive. The allele frequency of M694V among the FMF patients with radiographic sacroiliitis was significantly
higher in comparison with those without sacroiliitis (OR 4.3). When compared with the general population, the risk
ratios for SpA and AS among the FDRs of our FMF patients were 3.3 (95% CI; 2.0 to 5.5) and for AS 2.9 (95% CI;
1.3 to 6.4), respectively.
Conclusions: Our study suggests that a) factors other than HLA-B27 play a role in the association of FMF and SpA/AS;
b) MEFV gene variations may be one of the geographic/region-specific potential pathogenetic links between these two
disorders in the Turkish population.
Introduction
Familial Mediterranean fever (FMF) is an autoinflamma-
tory disease characterized by recurrent febrile attacks of
serositis [1]. Musculoskeletal features are common in
patients with FMF [1,2], and arthritis is the second most
common type of acute attack [1]. Typically this is acute
self-limiting monoarthritis affecting the large joints of the
lower limbs, and about 5% of FMF patients develop
protracted arthritis, mostly in the hips or knees [2]. These
features of the disease resemble spondyloarthritis (SpA).
Moreover sacroiliitis, which is the hallmark of SpA, is
reported to arise at a higher than expected frequency in
both Turkish and Jewish FMF patients with musculoskele-
tal symptoms [3-5]. However the current data on the role
of human leukocyte antigen (HLA)-B27 in the develop-
ment of sacroiliitis in FMF patients are controversial [4,5].
The gene responsible for FMF (designated MEFV) is
located on the short arm of chromosome 16 and encodes
an immunoregulatory protein known as pyrin or marenos-
trin [6,7]. The M694V polymorphism within the MEFV
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gene is the leading variation among Turkish and Sephardic
Jews and it has been demonstrated that arthritis is asso-
ciated with the presence of M694V [1,2]. There is also
some evidence that the M694V variation may be more fre-
quent in FMF patients with sacroiliitis [4]. FMF is mainly
prevalent in Jews, Turks, Armenians and Arabs, and the
carrier frequency of MEFV variations in these populations
has been reported to be as high as 39% [8,9]. This very
high frequency in these populations has prompted interest
in the MEFV status in seemingly healthy subjects. In this
regard, both basal and peak acute phase protein concen-
trations have been found over several months to be greater
in MEFV heterozygotes than in wild-type controls, regard-
less of the presence of gene variations [10]. It has been
speculated that the upregulation of the inflammatory
response may predispose MEFV carriers to certain types
of inflammatory conditions. Indeed, febrile episodes, acute
rheumatic fever and rheumatoid arthritis are reported to
be higher in frequency in MEFV carriers than in healthy
controls [11,12]. On the other hand, MEFV variations
were tested previously in several inflammatory conditions
and recent controlled studies have revealed that the
M694V allele frequency is significantly increased in anky-
losing spondylitis (AS) patients compared with controls
[13-15].
To further elucidate these phenomena in our present
study, we investigated the prevalence of SpA and AS in a
cohort of FMF patients. We also evaluated the frequency
of HLA-B27 and MEFV gene variations in patients with
FMF and AS. To evaluate the role of MEFV in determin-
ing the susceptibility to SpA, we also examined the first-
degree relatives (FDRs) of the patients in our study
cohort who we expected to have a higher carriage rate of
MEFV variations than the general population.
Materials and methods
The first 258 FMF patients who had been invited to the
outpatient clinic of our hospital to take part in an FMF
survival study [16] were examined for possible inclusion in
the subject cohort of our current study. Of these, 57 indi-
viduals were related to each other, thus, the first 201 unre-
lated patients were finally included in the analysis. All of
these patients fulfilled the previously defined criteria of
Livneh et al. for FMF [17]. The disease severity score for
these FMF patients was calculated in accordance with the
scoring criteria developed by the Sheba Medical Center
[18]. FDRs (full siblings, parents and children) of our 201
FMF patients who were at least 16 years of age were also
invited to the outpatient clinic for a formal evaluation.
All attending patients were examined using a standard
protocol for capturing patients with SpA and AS. A face
to face interview using a standardized questionnaire was
undertaken in each case to obtain demographic and
clinical data including the presence of back pain, the
characteristics of inflammatory back pain (IBP), and
other articular and extra-articular manifestations of SpA
(peripheral arthritis, enthesitis, uveitis, dactylitis, psoria-
sis, inflammatory bowel disease, the presence of a pre-
ceding infection, and family history for SpA). The
results of MEFV genotyping, the erythrocyte sedimenta-
tion rate (ESR) and C-reactive protein (CRP) levels were
extracted from the patients’ charts. All of the study par-
ticipants completed the validated Turkish versions of
the Bath ankylosing spondylitis disease activity index
(BASDAI) [19,20] and the Bath ankylosing spondylitis
functional index (BASFI) questionnaires [21,22]. In addi-
tion, all of the FMF patients in our cohort and their
FDRs were clinically examined by a rheumatology fellow
(OS) and a senior rheumatologist (SA).
The presence of IBP was judged according to the Calin
[23] and Berlin [24] criteria. The diagnoses of SpA and
AS were made based on the European Spondyloarthritis
Study Group (ESSG) [25] and the modified New York
(mNY) criteria [26], respectively. Axial SpA was defined
according to the imaging arm of the Assessment of Spon-
dyloArthritis International Society (ASAS) classification
criteria [27].
Standard pelvic radiographs were obtained in all
patients to assess the sacroiliac joints (SIJs). Each SIJ was
scored on radiographs according to the mNY criteria [26]
as follows: grade 0: normal; grade 1: suspicious; grade 2:
minimal abnormality with small localized erosions,
sclerosis without joint space alteration; grade 3: definite
abnormality with erosion, sclerosis, and joint space
widening or narrowing or partial ankylosis; grade 4: total
ankylosis of joint.
In patients with IBP but normal pelvic radiographs, mag-
netic resonance imaging (MRI) of the SIJs was ordered. In
FMF patients with IBP, assessment of HLA-B27 was also
ordered. MRI was performed with a 1.5-Tesla (T) system
(Philips Achieva, Eindhoven, Netherlands) using appropri-
ate surface coils. Sequences were: (1) paracoronal
T1-weighted (repetition time/echo time (TR/TE): 607 ms/
18 ms; (2) paracoronal dual echo T2-weighted fat-saturated
(spectral presaturation with inversion recovery (SPIR),
TR/TE: 2874 ms/100 ms); (3) paracoronal dual echo
proton density turbo spin echo (TR/TE: 2874 ms/12.5 ms).
For all sequences slice thickness was 3 mm.
MRI was considered positive for active sacroiliitis
according to the ASAS/Outcome Measures in Rheumatoid
Arthritis Clinical Trials (OMERACT) MRI working group
definition, that is the presence of at least one active lesion
in at least two consecutive slices, or the presence of more
than one lesion in only one slice [28].
After a series of training sessions for the standardiza-
tion of assessment, all radiographs and all SPIR and
T1-weighted sequences of paracoronal MR images were
read and scored by two independent readers (SA and
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AB), who were blinded to the demographic and clinical
features of the patients. Nineteen radiographs and
twenty-four MRI scan series were re-scored by each
reader for the calculation of intra-observer reliability. At
the initial reading sessions there was moderate agree-
ment between the two readers with regard to radio-
graphic scoring of SIJs (the intraclass correlation
coefficient (ICC) for the right and left SIJs were 0.647
and 0.682, respectively), and the two readers agreed on
the presence of inflammation at any site of the SIJ on
MRI in 91% of cases, with a к value of 0.623. ICC values
for the first reader were 0.634 and 0.656, for the right
and left SI joints, respectively, and the intra-observer
reliability for diagnosing bone marrow edema was good
(к = 0.750). ICC values for the second reader were 0.595
and 0.622 for the right and left SI joints, respectively,
and к = 0.625 for MRI reading.
This study was approved by Dokuz Eylul University
School of Medicine Ethical Committee for Clinical and
Laboratory Research (protocol number 85/2009) and all
patients gave written informed consent.
Statistical analyses
Unless otherwise stated, the values in this paper are pre-
sented as the mean ± SD, or percentage as appropriate.
Comparisons of categorical data between groups were
made using the chi-square test. The Mann-Whitney
U-test was used to analyze continuous data. To compare
the observed frequency of SpA and AS in FDRs of our
FMF patients, risk ratios were calculated using prevalence
figures for the general Turkish population [29]. The intra-
and inter-observer reliability for SIJ scoring according to
the mNY criteria was analyzed by the calculation of the
ICC (single measures for a single rater, average measures
for different raters). Agreement for active inflammation
identified on MRI was analyzed by cross-tabulation and к
statistics. In cases on which two readers disagreed, a joint
reading session was held in order to reach a consensus. All
statistical tests were two-tailed and a P-value < 0.05 was
considered statistically significant. Statistical analyses were
performed using StatsDirect Statistical Software, version
2.0.0 (Cheshire, UK).
Results
Frequency of SpA and related features in FMF patients
The demographic features of the FMF study subjects are
summarized in Table 1. Current or previous low back pain
was reported by 157 (78%) of these patients, of whom 44
(28%) met the Calin criteria and 33 (21%) the Berlin
criteria for IBP. None of our patients had uveitis and one
had inflammatory bowel disease. Among our cohort, 70
cases (34.8%) fulfilled the ESSG criteria for SpA. Pelvic
radiographs were obtained for 188 patients (93.5%) and
radiographic sacroiliitis was diagnosed in 16 of these cases,
of whom 15 (13 female (52%), median age (range) 46 (17
to 65) years) met the mNY criteria for AS (Table 2). The
remaining patient with radiographic sacroiliitis was
diagnosed with psoriatic arthritis.
The results of MEFV genotyping in our FMF patients
with radiographic sacroiliitis are shown in Table 2.
MEFV variant analysis was available for 146 FMF patients
who did not have sacroiliitis and both the allele frequency
(23/30 vs 126/292; P = 0.0005, odds ratio (OR) 4.3, 95%
CI 1.8, 10.4) and the homozygosity rate (9/15 vs 30/146;
P = 0.002, OR 5.8, 95% CI 1.9, 17.6) for M694V were
found to be significantly increased in the FMF patients
with AS. The carriage rate of the M694V polymorphism
was found to be higher in patients with both FMF and
AS but this finding was not statistically significant (OR
7.3, 95% CI 0.9, 57.1). HLA-B27 was genotyped in
13 patients with sacroiliitis and all were negative.
MRI analysis of the SIJs was obtained in 23 out of the
29 FMF patients in our cohort who had IBP, but not
radiographic sacroiliitis. Four patients were found to
Table 1 Demographic features of the familial Mediterranean fever patients and their first-degree relatives
Characteristics Familial Mediterranean fever patients (FMF) (n = 201) First degree relatives of FMF patients (n = 319)
Female, number (%) 105 (52%) 189 (59%)
Age, years, mean ± SD 39.6 ± 12.0 44.6 ± 15.5
Education level, mean ± SD 10.6 ± 3.7 8.6 ± 4.4
Disease severity score
Mild, % individuals 37.5 -
Moderate, % individuals 13.5 -
Severe, % individuals 49.0 -
ESR, mm/h, mean ± SD 20.2 ± 17.7 17.5 ± 14.1
CRP, mg/L, mean ± SD 9.4 ± 19.7 4.2 ± 6.0
BASFI score, mean ± SD 0.9 ± 1.4 1.0 ± 1.6
BASDAI score, mean ± SD 2.4 ± 2.0 2.3 ± 2.1
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis
functional index.
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have bone marrow edema on MRI, all of whom were
carriers for M694V (one homozygous, one compound
heterozygous (M694V/V726A), and two heterozygous)
and negative for HLA-B27. In total 18 patients were
classified with axial SpA according to the imaging arm
of the ASAS criteria. Two patients with sacroiliitis on
imaging did not fulfill the entry criterion of age at onset
of symptoms as specified in the ASAS criteria. Hence, in
our FMF patients the frequency of AS was 7.5% and the
frequency of axial SpA was 8.9%.
Frequency of SpA and related features in the FDRs of the
FMF patients examined in this study
In the second part of our study, we included the FDRs
(16 years and over) of the 201 probands in our patient
cohort. Of the total 1,039 FDRs of these patients, 892 were
alive at the time of the study. We were unable to contact
95 of these FDRs after at least three attempts, and another
84 FDRs who had also been diagnosed with FMF were
excluded from the study. Of the remaining 713 FDRs, 319
agreed to participate. The case recruitment process for
FDRs of our FMF patients is summarized in Figure 1 and
some of the demographic and clinical features of our
study groups are shown in Table 1.
An episode of low back pain, even if in the distant past,
was reported by 233 (73%) of the 319 FDR individuals.
The Calin and Berlin criteria for IBP were met by 32
(13.7%) and 20 of these subjects (8.6%), respectively. A pel-
vic radiograph was taken in 277 (86.8%) FDRs of whom
nine had unequivocal sacroiliitis as determined using the
mNY criteria. On reviewing the medical records of the
394 FDRs who did not attend, one additional AS patient
was identified. MRI analysis of the SIJs was performed in
19 out of the 27 FDRs of FMF patients who had IBP but
not radiographic sacroiliitis. Bone marrow edema was
detected by MRI in seven of these cases. Twenty-six FDRs
fulfilled the ESSG criteria for SpA. Eleven (1.5%) FDRs
were classified as axial SpA according to the ASAS criteria.
Five patients with AS and one with sacroiliitis on MRI
could not be diagnosed as axial SpA since they did not ful-
fill the entry criterion for age at onset, or duration of
symptoms as per the ASAS criteria. Six FDRs had psoria-
sis, three had uveitis and one had inflammatory bowel dis-
ease. One FDR who had uveitis also had bilateral grade
four sacroiliitis. Moreover, two individuals with Behcet’s
syndrome, two with rheumatoid arthritis and one with
undifferentiated arthritis were identified among the FDRs.
The prevalence of SpA (according to the ESSG criteria)
Table 2 Characteristics of patients with both familial Mediterranean fever (FMF) and ankylosing spondylitis
Patient number FMF/FDR Clinical criteria of mNY Arthritis Enthesitis Uveitis MEFV typing HLA-B27 typing
1 FMF Yes Yes Yes No M694V/M680I Negative
2 FMF Yes Yes Yes No M694V/V726A Negative
3 FMF Yes Yes Yes No M694V/M694V Negative
4 FMF Yes No No No M680I/V726A Negative
5 FMF Yes Yes Yes No M694V/M694V Negative
6 FMF Yes No No No M694V/M680I Negative
7 FMF Yes Yes No No M694V/M694V Negative
8 FMF Yes Yes No No M694V/M694V ND
9 FMF Yes No Yes No M694V/M694V ND
10 FMF Yes Yes No No M694V/M694V Negative
11 FMF Yes No Yes No M694V/W Negative
12 FMF Yes Yes Yes No M694V/M694V Negative
13 FMF Yes Yes No No M694V/M694I Negative
14 FMF Yes No Yes No M694V/M694V Negative
15 FMF Yes Yes No No M694V/M694V Negative
16 FDR Yes Yes Yes No W/W Negative
17 FDR Yes No No No ND Negative
18 FDR Yes No No No ND Negative
19 FDR Yes No No No ND ND
20 FDR Yes Yes No Yes M694V/W ND
21* FDR Yes No No No NA NA
22 FDR Yes No No No ND ND
23 FDR Yes No No No ND ND
24 FDR Yes No No No ND ND
25 FDR Yes No No No ND ND
*Patient identified by medical record review. FDR, first-degree relative; M, male; F, female; ND, not done; NA, not available; mNY, modified New York.
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and AS in the 713 FDRs was calculated as 3.6% and 1.4%,
respectively. Based on a general population prevalence of
1.09% for SpA (according to the ESSG criteria) and of
0.49% for AS, as observed in a previous study conducted
in our region [29], the risk ratio for SpA was estimated at
3.3 (95% CI 2.0, 5.5) and at 2.9 (95% CI 1.3, 6.4) for AS
among the FDRs of FMF patients. When only the parents
(n = 275) were included in this analysis, the corresponding
risk ratios were 4.9 (95% CI 2.7, 9.0) and 3.7 (95% CI 1.3,
10.4), respectively.
Discussion
The results of our present study reveal increased preva-
lence of SpA and AS among FMF patients. Our results
thus confirm previous observations. The first case of
FMF in association with AS was described in 1963 [30].
Thereafter, this association was reported in numerous
other case reports. However, there are only a few studies
to date that have systematically evaluated the relationship
between FMF and SpA. In the first such study of this nat-
ure, 3,000 FMF patients were initially screened for the
presence and manifestations of SpA [5], and among
them, 160 patients with chronic arthritis were included
in the subsequent study. In the aforementioned study,
SpA was defined as the presence of chronic arthritis,
inflammatory back/neck pain and sacroiliitis. Of the 160
FMF patients with chronic arthritis, 11 met the criteria
for SpA of FMF (and actually all the subjects in this pre-
vious cohort fulfilled the New York criteria for AS).
Moreover, the prevalence of SpA was estimated as 0.4%
among the 3,000 initial patients. The HLA-B27 test was
negative in all cases of SpA among these FMF patients.
The authors excluded three other patients who had bilat-
eral sacroiliitis, bamboo spine or were HLA-B27 positive.
Although these cases met the authors’ criteria of SpA of
FMF they were interpreted as suffering from AS that
coincided with their FMF, and were therefore clinically
and genetically different from the other 11 patients.
However, they also considered the possibility that these
three patients might represent a more severe form in the
clinical spectrum of FMF-related SpA, perhaps associated
with the presence of HLA-B27.
In another earlier study from Turkey, the clinical and
demographic features of 503 FMF patients were evalu-
ated and the phenotypic differences between patients
with and without amyloidosis were analyzed [3]. In this
previous study, the prevalence of clinically and radiologi-
cally proven sacroiliitis was 6% (3/50) in patients with
amyloidosis, and was 11% (50/453) in patients without
amyloidosis. Overall, the frequency of sacroiliitis was
Figure 1 Flow-chart summarizing the participant recruitment process used in this study. FMF, familial Mediterranean fever.
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10.5%. However, the authors did not provide detailed
definitions of clinical or radiographic sacroiliitis or infor-
mation regarding the MEFV or HLA-B27 status of their
FMF patients with sacroiliitis.
Recently in another study from Turkey [4], the authors
retrospectively reviewed the medical records of 256 FMF
patients to evaluate the presence of one or more muscu-
loskeletal manifestations (inflammatory low back pain,
arthritis and enthesitis). Of the 70 FMF patients with mus-
culoskeletal findings 55 agreed to participate in the study.
Direct radiographs of the SIJs were used to grade the
sacroiliitis and MRI analysis of the SIJs was performed in
patients with sacroiliitis grade 0, 1 or 2 as determined on
direct radiography. In the abovementioned study there
were eight patients (3.1%) diagnosed with a grade 3 to 4
sacroiliitis by direct radiography. All of these cases were
male and were HLA-B27-positive, and none had signs of
vertebral involvement. There were an additional 10
patients (3.1%) with sacroiliitis identified on MRI, all of
whom were HLA-B27-negative. Overall the frequency of
sacroiliitis among all FMF patients was reported to be 7%.
The main difference between our current study and pre-
vious reports such as those discussed here is that we eval-
uated all of the cases in a cohort of 201 patients rather
than a select group of patients with articular or musculos-
keletal involvement. In addition to the increased preva-
lence of SpA and AS found among our unselected FMF
patients, we show from our current analysis that all of our
tested patients with AS were negative for HLA-B27. This
finding suggests that factors other than HLA-B27 play a
role in the association of FMF and AS. MEFV itself may
be the link between these two disorders since we also
revealed an association between the development of AS in
FMF patients and the M694V variation in the MEFV gene.
This is in line with a previous observation from Turkey [4]
which showed that M694V is the most common variation
in FMF patients with both radiographic and MRI evidence
of sacroiliitis. However, in the latter study most of the
patients with radiographic sacroiliitis had only one MEFV
variant and all of them were HLA-B27 positive. Moreover,
in our previous report, we reviewed 22 adult case descrip-
tions [31], of which MEFV gene variants were analyzed in
15 cases. Twelve patients were homozygous for M694V,
two patients were compound heterozygotes (M694V/
M680I; M680I/V726) and one patient had a single poly-
morphism (M680I/-).
To further delineate the role ofMEFV in the susceptibil-
ity to SpA and AS, we also assessed the FDRs of FMF
patients who were predicted to have a higher carrier fre-
quency. We also analyzed the parents of our probands for
obligate carrier status. We found significantly increased
frequency of AS and SpA in the FDRs of FMF patients. In
addition, the frequency of AS among the parents of our
FMF patients was also high in comparison with the gen-
eral population.
In FMF patients, mutations are found throughout the
MEFV gene; however, those producing the most severe
phenotype are clustered in exon 10, which encodes the
B30.2/SPRY domain (PRYSPRY), at the C terminus of the
pyrin protein. The exact function of pyrin still remains
somewhat controversial. N-terminal pyrin appears to acti-
vate nuclear factor-B (NF-B) through the increased cal-
pain mediated degradation of inhibitor of NF-B (IB)-a
[32]. Recently, it was demonstrated that pyrin can interact
with the apoptosis-associated speck-like protein (ASC),
which has a caspase-recruitment domain (CARD) [33]. In
addition to its role in apoptosis, ASC also nucleates
inflammasome complexes through the homotypic interac-
tions of its pyrin domain and CARD with NLRP proteins
and inflammatory caspases, respectively [34]. Thus, ASC
may mediate the activation of IL-1. The direct interaction
of pyrin with ASC also uncovers potential molecular
mechanisms for the abrupt onset inflammatory attacks
associated with FMF [32].
Although the association between AS susceptibility and
the class I molecule HLA-B27 is one of the strongest
known HLA disease associations, the molecular mechan-
isms underlying disease pathogenesis still require clarifica-
tion. In fact, the inability to explain this association on the
basis of antigen presentation and major histocompatibility
complex region, which reveal only half of the genetic
susceptibility to AS, has led to alternative hypotheses [32].
The IL-1 pathway might be one of the pathogenetic
mechanisms involved in AS. Candidate gene analyses have
implicated the IL-1 cluster of genes as an AS susceptibility
locus [35] and subsequent meta-analysis of whole genome
linkage scans supported the linkage of chromosome 2q
(IL-1 gene cluster) with AS [36]. Further, endoplasmic
reticulum associated aminopeptidase 1 (ERAP1), a gene
that was shown to be the strongest non-MHC gene asso-
ciated with AS [37], also modulates the proinflammatory
cytokines IL-1, IL-6, and TNF by cleaving their receptors
at the cell surface [32].
In our present study, consecutive patients were included
in order to minimize a possible bias for recruitment of
patients with a history of SpA or AS, and a large number
of relatives were also assessed. We evaluated both the
patients and their FDRs using the same standardized pro-
tocol, which included a screening questionnaire, clinical
examinations and radiography. One of the main limitations
of our study may be its hospital-based nature. The fre-
quency of more severe disease and allied conditions may
be higher in those patients attending hospital visits regu-
larly. Similarly, the frequency of symptomatic individuals
may be higher in those relatives who agreed to participate
in the study.
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Unfortunately, we could not perform genetic analysis in
the FDRs due to lack of resources, thus we could not use
Amor, or the HLA-B27 arm of the ASAS classification
criteria. Another limitation of this study was that only
319 (45%) of the available FDRs could be examined.
However, our calculated prevalence rates represent the
minimum prevalence, since we assumed that all of the
potential subjects who did not participate in this study
did not have SpA.
Conclusions
The results of our present study not only confirmed an
increased prevalence of SpA and AS among FMF patients,
but also indicated for the first time that SpA and AS are
more common among the FDRs of FMF patients than in
the general population. The increased prevalence of SpA,
including AS, among FMF patients as well as in their
FDRs, provide additional evidence that there is a link
between SpA/AS and FMF. The higher frequency of
M694V among FMF patients with radiographic sacroiliitis
than those without this disorder, suggest that MEFV gene
variations may be the potential pathogenic link between
the two disorders and can be recognized as a geographic
region-specific risk factor for SpA/AS, affecting a common
inflammatory pathway of IL-1 in the pathogenesis of these
diseases.
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